Joy Maulik
Family · Salisbury, MDNPI 1508226713
Payments from drug & device makers
Across 285 payments — averaging $165.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$34K
- Dendreon Pharmaceuticals LLC$7K
- Johnson & Johnson$3K
- AbbVie$486
- Progenics Pharmaceuticals, Inc.$412
- Astellas Pharma US Inc$333
- plus $2K from 22 others
What the payments were for
- Consulting fees$6,82814%
- Speaking & faculty fees$21,40245%
- Travel & lodging$10,41722%
- Food & beverage$8,19917%
- Education$3201%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 92 | $34,089 |
| Dendreon Pharmaceuticals LLC | 27 | $6,796 |
| Johnson & Johnson(2 entities) | 41 | $2,985 |
| AbbVie | 24 | $486 |
| Progenics Pharmaceuticals, Inc. | 10 | $412 |
| Astellas Pharma US Inc | 12 | $333 |
| Pfizer | 14 | $323 |
| Merck | 12 | $302 |
| Teleflex LLC | 5 | $274 |
| Immunitybio, Inc. | 1 | $135 |
| Novartis | 5 | $104 |
| Medtronic | 3 | $103 |
| Boston Scientific | 5 | $102 |
| Sumitomo Pharma America, Inc. | 5 | $95 |
| Olympus America Inc. | 3 | $91 |
| Endo USA, Inc. | 5 | $89 |
| Tempus AI, Inc | 4 | $87 |
| Amgen | 3 | $65 |
| Accord Healthcare, Inc. | 2 | $49 |
| Myriad Genetic Laboratories, Inc. | 3 | $42 |
| 180 Medical, Inc. | 1 | $40 |
| Foundation Medicine, Inc. | 2 | $34 |
| Tolmar, Inc. | 1 | $29 |
| Urogen Pharma, Inc. | 1 | $25 |
| Tolmar Pharmaceuticals, Inc. | 1 | $23 |
| Urovant Sciences Inc | 1 | $21 |
| Laborie Medical Technologies Corp. | 1 | $18 |
| Endo Pharmaceuticals Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$47,166 in reported general payments places this provider in the 95th percentile of 2,843 family providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 22 | $330,622 |
| ErleadaApalutamide | 23 | $322,528 |
| OrgovyxRelugolix | 22 | $60,903 |
| GemtesaVibegron | 68 | $39,530 |
| Tamsulosin Hcl | 1,057 | $21,121 |
| MyrbetriqMirabegron | 28 | $14,850 |
| Finasteride | 363 | $7,331 |
| Silodosin | 45 | $2,946 |
| Oxybutynin Chloride ErOxybutynin Chloride | 95 | $2,173 |
| Dutasteride | 23 | $1,506 |
| Trospium Chloride ErTrospium Chloride | 15 | $1,496 |
| Tadalafil | 27 | $1,301 |
| Testosterone Cypionate | 53 | $1,242 |
| Oxybutynin Chloride | 38 | $1,041 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 22 | $688 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $333 | $345,47250 claims |
| Johnson & JohnsonErleada | $2,985 | $322,52823 claims |
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $95 | $100,43490 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,843 family providers in Maryland.
Other family in Salisbury
- Caroline MansySalisbury$106K
- Sarah ProffitSalisbury$10K
- Donna GraySalisbury$10K
- Ariana ChaoLutherville$727K
- Erika HoffmanPotomac$226K
- Hazel Jones-ParkerBaltimore$96K
- Brittany WilsonBaltimore$88K
- Meredith SagalHunt Valley$82K
- Sharon Dudley-BrownBel Air$67K
- Kristin AttiogbeChevy Chase$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.